USD10
CHRS azioni
Informazioni su Coherus OncologyCoherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
USD10
CHRS azioni
Informazioni su Coherus OncologyCoherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Statistiche
FINESTRA DI NEGOZIAZIONE
Chiusa
APRE ALLE
27 mar at 13:30 GMT+0
Capitalizzazione di mercato
244,32 Mln USD
PREZZO DI APERTURA
1,63 USD
MINIMO (1 anno)
0,71 USD
MASSIMO (1 anno)
2,62 USD
MINIMO (24H)
1,62 USD
MASSIMO (24 ore)
1,68 USD
VOLUME (24 ore)
684,11K USD
1,25%
Cronologia dei prezzi
Time | Price | Change |
|---|---|---|
Oggi | 1,63 USD | 0,00% |
1 giorno | 1,69 USD |